Fexuprazan vs esomeprazole for endoscopic submucosal dissection-induced gastric ulcer healing: A double-blind randomized controlled trial

Figure 4 Exploratory analysis of the model-estimated time to a 99% reduction in ulcer area according to baseline ulcer area. In this per-protocol analysis, the time to a 99% reduction in ulcer area was estimated for each patient using an exponential decay model based on baseline and 4-week ulcer areas. A: Overall (40.31 days vs 47.22 days; P = 0.045); B: ≥ 800 mm² (42.89 days vs 47.62 days; P = 0.039); C: < 800 mm² (41.03 days vs 44.83 days; P = 0.588), shown for the fexuprazan vs esomeprazole groups. The curves are model-based extrapolations beyond the last observed measurement and do not represent observed times to endoscopic healing.